世界科学技术-中医药现代化
世界科學技術-中醫藥現代化
세계과학기술-중의약현대화
WORLD SCIENCE AND TECHNOLOGY-MODERNIZATION OF TRADITIONAL CHINESE MEDICINE
2015年
6期
1220-1224
,共5页
川芎嗪%异丙托溴铵%支气管哮喘%肺功能%炎性因子%瘦素
川芎嗪%異丙託溴銨%支氣管哮喘%肺功能%炎性因子%瘦素
천궁진%이병탁추안%지기관효천%폐공능%염성인자%수소
Tetramethylpyrazine%ipratropium bromide%bronchial asthma%pulmonary function%inflammatory factor%leptin
目的：探讨川芎嗪联合异丙托溴铵治疗支气管哮喘的临床疗效及对患者炎性因子和瘦素的影响。方法：124例符合纳入标准的支气管哮喘患者按照随机数字表法随机分为对照组（n=62）和观察组（n=62）。常规治疗基础中，对照组给予异丙托溴铵治疗，观察组在对照组的基础上联合应用川芎嗪治疗。观察比较两组患者治疗有效率、肺功能、炎性因子、瘦素水平及不良反应发生情况。结果：观察组的治疗总有效率为96.8%，明显高于对照组87.1%的总有效率（P<0.05）。与对照组相比，观察组治疗后肺功能指标PEF、FEV1/FVC升高，炎性因子IL-6、IL-4水平降低，IL-12水平升高，比较均有统计学差异（P<0.05）。在治疗后的1、2、4周时，观察组瘦素水平均显著低于对照组（P<0.05）。治疗过程中，未出现严重不良反应，观察组和对照组的不良反应发生率分别为11.3%和14.5%，组间比较无统计学差异（P>0.05）。结论：川芎嗪联合异丙托溴铵治疗支气管哮喘疗效可靠，能够显著提高临床疗效，改善肺功能，减轻炎性反应，降低瘦素水平，且不良反应轻微，临床上值得进一步研究。
目的：探討川芎嗪聯閤異丙託溴銨治療支氣管哮喘的臨床療效及對患者炎性因子和瘦素的影響。方法：124例符閤納入標準的支氣管哮喘患者按照隨機數字錶法隨機分為對照組（n=62）和觀察組（n=62）。常規治療基礎中，對照組給予異丙託溴銨治療，觀察組在對照組的基礎上聯閤應用川芎嗪治療。觀察比較兩組患者治療有效率、肺功能、炎性因子、瘦素水平及不良反應髮生情況。結果：觀察組的治療總有效率為96.8%，明顯高于對照組87.1%的總有效率（P<0.05）。與對照組相比，觀察組治療後肺功能指標PEF、FEV1/FVC升高，炎性因子IL-6、IL-4水平降低，IL-12水平升高，比較均有統計學差異（P<0.05）。在治療後的1、2、4週時，觀察組瘦素水平均顯著低于對照組（P<0.05）。治療過程中，未齣現嚴重不良反應，觀察組和對照組的不良反應髮生率分彆為11.3%和14.5%，組間比較無統計學差異（P>0.05）。結論：川芎嗪聯閤異丙託溴銨治療支氣管哮喘療效可靠，能夠顯著提高臨床療效，改善肺功能，減輕炎性反應，降低瘦素水平，且不良反應輕微，臨床上值得進一步研究。
목적：탐토천궁진연합이병탁추안치료지기관효천적림상료효급대환자염성인자화수소적영향。방법：124례부합납입표준적지기관효천환자안조수궤수자표법수궤분위대조조（n=62）화관찰조（n=62）。상규치료기출중，대조조급여이병탁추안치료，관찰조재대조조적기출상연합응용천궁진치료。관찰비교량조환자치료유효솔、폐공능、염성인자、수소수평급불량반응발생정황。결과：관찰조적치료총유효솔위96.8%，명현고우대조조87.1%적총유효솔（P<0.05）。여대조조상비，관찰조치료후폐공능지표PEF、FEV1/FVC승고，염성인자IL-6、IL-4수평강저，IL-12수평승고，비교균유통계학차이（P<0.05）。재치료후적1、2、4주시，관찰조수소수평균현저저우대조조（P<0.05）。치료과정중，미출현엄중불량반응，관찰조화대조조적불량반응발생솔분별위11.3%화14.5%，조간비교무통계학차이（P>0.05）。결론：천궁진연합이병탁추안치료지기관효천료효가고，능구현저제고림상료효，개선폐공능，감경염성반응，강저수소수평，차불량반응경미，림상상치득진일보연구。
This study was aimed to investigate the clinical effect of tetramethylpyrazine in combination with ipratropium bromide in the treatment of bronchial asthma and its effects on inflammatory factors and leptin. According to inclusion criteria, a total of 124 bronchial asthma cases were included and randomly divided into two groups, which were the control group (n = 62) and the observation group (n = 62) with the random number table. Besides conventional treatments, the control group was given ipratropium bromide; while the observation group was given tetramethylpyrazine in combination with ipratropium bromide. Then, comparisons were made between two groups on the therapeutic efficacy rate, pulmonary function, inflammatory factor, leptin, and incidence of adverse reactions. The results showed that the total therapeutic efficacy rate was 96.8% in the observation group, which was obviously higher than that of 87.1% in the control group (P < 0.05). In comparison with the control group, the posttreatment pulmonary function indexes PEF and FEV1/FVC increased, inflammatory factors IL-6 and IL-4 decreased, and IL-12 increased in the observation group with statistical significance (P < 0.05). One week, 2 weeks and 4 weeks after the treatment, the level of leptin in the observation group was significantly lower than that in the control group (P < 0.05). During the treatment, there were no severe adverse reactions. The incidence of adverse reactions in the observation group was 11.3%, which was statistically the same with that of 14.5% in the control group (P > 0.05). It was concluded that tetramethylpyrazine in combination with ipratropium bromide was effective for bronchial asthma treatment, which can significantly increase curative efficacy, improve pulmonary function, alleviate inflammatory reaction and reduce leptin level with minor adverse reactions. It required further studies in the clinical practice.
